A first example is the phase Ib study (NCT01656642) using atezolizumab (an anti-PDL1) in combination with vemurafenib or vemurafenib plus cobimetinib in patients with BRAF-V600 metastatic melanoma [163]. This evidence concerns the gene BRAF and metastatic melanoma.